Development of innovative T-cell immunotherapy for hematological malignancies

DOI Web Site PubMed
  • OCHI Toshiki
    Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine Division of Immune Regulation, Proteo-Science Center, Ehime University

Bibliographic Information

Other Title
  • 造血器腫瘍に対する革新的T細胞免疫療法
  • ゾウケツキ シュヨウ ニ タイスル カクシンテキ Tサイボウ メンエキ リョウホウ

Search this article

Abstract

<p>With the emergence of cancer immunotherapy, T cells have played important roles in inducing antitumor responses. Many types of antitumor receptors, which possess tumor-binding sites and T-cell activation sites, have been developed. For example, genetically engineered T-cell receptor, chimeric antigen receptor, and bispecific antibody can help us to educate and activate T cells specific for certain tumors. To generate optimal antitumor receptors, (1) selection/distribution of tumor antigens, (2) affinity/specificity and cross-reactivity of antitumor receptors, and (3) T-cell activation signals delivered from antitumor receptors should be considered. Accordingly, we explain how antitumor receptors recognize target antigens and summarize the mechanisms for on-target/off-target reactivity induced by T cells redirected with antitumor receptors. Furthermore, we discuss how antitumor receptors can be optimized for the development of next-generation cancer immunotherapy.</p>

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 60 (7), 824-833, 2019

    The Japanese Society of Hematology

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top